Home Infusion for Multiple Sclerosis: Ocrevus, Tysabri, and What Patients Should Know

June 11, 2026

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath surrounding nerve fibers, disrupting signal transmission and causing progressive neurological symptoms. For patients with relapsing MS and certain forms of progressive MS, high-efficacy IV biologic therapies have become a cornerstone of disease management.


Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated infusion center visits every six months or four weeks. Pharmko supports MS patients and their neurologists across 22+ states with full clinical coordination and nursing support.


IV Biologic Therapies Used in Multiple Sclerosis


Ocrevus (ocrelizumab)

Ocrevus is an anti-CD20 monoclonal antibody that depletes B cells, a key driver of MS inflammation and neurodegeneration. It is FDA-approved for both relapsing MS and primary progressive MS (PPMS), making it the first therapy approved for PPMS. Ocrevus is administered twice yearly by IV infusion, with the first dose split into two infusions two weeks apart.


Each infusion takes approximately 3.5 hours for subsequent doses (the initial doses take up to 5 hours due to slower administration rates). Vital sign monitoring is required throughout. Pre-medications, methylprednisolone, an antihistamine, and acetaminophen, are given before each infusion to reduce the risk of infusion-related reactions.


Tysabri (natalizumab)

Tysabri is an alpha-4 integrin inhibitor that prevents immune cells from crossing into the central nervous system. It is administered monthly by IV infusion over approximately one hour. Tysabri is highly effective for relapsing MS but carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the JC virus, that requires regular monitoring and patient stratification.


Patients on Tysabri are tested for JC virus antibodies periodically, and their neurologist determines whether the benefit-risk profile supports continued therapy. This monitoring context is an important part of home infusion coordination.


Lemtrada (alemtuzumab)

Lemtrada is administered in two treatment courses, a 5-day course in year one and a 3-day course in year two, typically in a supervised clinical setting due to its intensive monitoring requirements. It is not commonly administered at home, but post-treatment monitoring visits can be coordinated through Pharmko when clinically appropriate.


Who Qualifies for Home Infusion of MS Biologics?


Home infusion for MS therapies is appropriate for patients who have:


  • Completed their initial infusion doses in a supervised clinical or infusion center setting without significant reactions
  • Received pre-infusion medications per protocol and tolerated them without complications
  • Been assessed by their neurologist as stable and suitable for home-based administration
  • A home environment that supports safe IV infusion with nursing oversight


The decision is made in collaboration between the patient and neurologist. Pharmko works directly with neurology practices to manage the clinical handoff from infusion center to home.


What to Expect During a Home MS Infusion


Before the infusion

A Pharmko nurse reviews your current medications, confirms you have no active infections, and administers pre-medications as ordered. Baseline vital signs are taken and documented.


During the infusion

Your nurse remains present for the full infusion, monitors vital signs at scheduled intervals, and responds immediately to any infusion-related reaction. The rate is slowed or the infusion paused if you experience flushing, chest tightness, or other symptoms.


After the infusion

Vital signs are checked before the nurse departs. Your neurologist's office receives a clinical summary. Know which symptoms require an immediate call after an Ocrevus or Tysabri infusion, delayed reactions can occur in the 24 hours following treatment.


Insurance Coverage for MS Infusion Therapy


Ocrevus and Tysabri are covered under the medical benefit by Medicare Part B and most commercial insurance plans. Prior authorization is required and must include documentation of MS diagnosis, relapse history, and prior treatment history. Pharmko manages the authorization process and coordinates with your neurologist's office to compile the necessary clinical documentation.


For patients interested in a broader overview of biologic therapies for autoimmune conditions, our guide on home infusion for autoimmune diseases provides useful context across conditions.


Contact Pharmko to start a referral: 1-877-540-2003


Person living with end stage renal disease going about an ordinary morning at home
September 1, 2026
Straight answers to what people on dialysis ask most: nutrition, phosphate, energy, travel, and the emotional weight of ongoing treatment.
Handwritten list of questions prepared for a dialysis appointment about IDPN therapy
September 1, 2026
The questions worth bringing to your nephrologist or dietitian before starting intradialytic parenteral nutrition, grouped and ready to print.
Adult daughter and her mother reviewing a delivery schedule together in the kitchen at home
September 1, 2026
A practical guide for caregivers: what your role is, what the pharmacy can share with you, what to keep track of, and how to protect your own energy.
Family sharing a meal at home while one member on parenteral nutrition joins the table
September 1, 2026
Whether you can eat on parenteral nutrition, why appetite and taste change, and how to handle meals with family while receiving IV nutrition.
Suitcase packed with a small cooler and paperwork for traveling while on parenteral nutrition
August 31, 2026
How to plan a trip on TPN or home parenteral nutrition: supplies, refrigeration, air travel documentation, and how far ahead to call your pharmacy.
Home delivery of TPN supplies unpacked on a kitchen table during the first week of therapy
August 31, 2026
A day-by-day look at starting total parenteral nutrition at home: the first delivery, the first infusion, night one, and when to call for help.
Dialysis center staff coordinating phosphate binder supply with a pharmacy partner
August 11, 2026
What dialysis centers should look for in a phosphate binder supply partner: reliable delivery, formulary breadth, insurance support, and coordination.
Renal dietitian reviewing phosphate levels with a dialysis patient
August 11, 2026
How hyperphosphatemia is managed in ESRD dialysis patients, diet, dialysis, and phosphate binders, and why reliable binder supply keeps therapy on track.
July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Show More